Age-related copy number variations and expression levels of F-box protein FBXL20 predict ovarian cancer prognosis

Shuhua Zheng,⁎, Yuejun Fu

A R T I C L E   I N F O

Article history:
Received 13 May 2020
Received in revised form 13 August 2020
Accepted 21 August 2020

A B S T R A C T

About 70% of ovarian cancer (OvCa) cases are diagnosed at advanced stages (stage III/IV) with only 20–40% of them survive over 5 years after diagnosis. A reliably screening marker could enable a paradigm shift in OvCa early diagnosis and risk stratification. Age is one of the most significant risk factors for OvCa. Older women have much higher rates of OvCa diagnosis and poorer clinical outcomes. In this article, we studied the correlation between aging and genetic alterations in The Cancer Genome Atlas Ovarian Cancer dataset. We demonstrated that copy number variations (CNVs) and expression levels of the F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), a substrate recognizing protein in the SKP1-Cullin1-F-box-protein E3 ligase, can predict OvCa overall survival, disease-free survival and progression-free survival. More importantly, FBXL20 copy number loss predicts the diagnosis of OvCa at a younger age, with over 60% of patients in that subgroup have OvCa diagnosed at age less than 60 years. Clinicalpathological studies further demonstrate the correlation between aging and genetic alterations, including accumulation of mutations, epigenetic modifications, and copy number variations (CNVs), may offer new clues in identifying OvCa diagnostic and screening biomarkers.

Introduction

Despite intensive treatment with surgical cytoreduction and platinum-based chemotherapy, ovarian cancer (OvCa) remains the most lethal gynecologic malignancy worldwide with relapses developed in the majority of advanced-stage cases (stage III/IV) [1,2]. About 70% of cases are diagnosed at advanced stages, with only 20–40% of them survive over 5 years after diagnosis [3]. A reliably screening and diagnostic marker can enable early OvCa diagnosis, risk stratification, and treatment planning.

Studies of age-specific incidence rates identified that the mean ages at OvCa diagnosis for BRCA1 and BRCA2 mutant patients were 51.3 and 61.4 years, respectively [4]. Therefore, prophylactic bilateral salpingo-oophorectomy (BSO) before age 40 for BRCA1 mutated and age 45 for BRCA2 mutated patients was recommended [4]. However, over 10% of the general population carry germline BRCA mutations [5,6]. Indeed, less than 21% of OvCa patients carry BRCA1 mutation and 8% have BRCA2 mutation [5,6]. The mutation rates of other OvCa risk-conferring genes such as RAD51C, RAD51D, BRIP1, FANC, and the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 mutations are less than 1% in the general population [7]. Therefore, mutations account for only a small fraction of OvCa cases, and the majority of the population will not benefit from the screening of these genetic alterations.

Age is one of the biggest independent risk factors for the disease diagnosis. Older OvCa patients often have poorer clinical outcomes [8]. Aging is associated with an increased prevalence of frailty, comorbidities, progressive decrease of organ function, as well as adverse drug reactions due to decreasing therapeutic window and distribution volume [9]. However, clinical studies identified that older patients (over 70 years) experienced the same percentage of morbidity with no significant difference in survival when compared with younger (under 70 years) women who were equally debulked [10]. Further studies demonstrated that elderly (65–75 years) and very elderly (>75 years) patients could tolerate radical surgery without an increase of morbidity rates when compared with those reported in younger patients, indicating older age is not a risk factor for aggressive surgical cytoreduction [11]. Clinical trials of chemotherapy with carboplatin/paclitaxel versus cisplatin/paclitaxel following cytoreductive surgery also demonstrated that OvCa patients over the age of 70 could tolerate the combinational treatment regimens [12]. Therefore, the alteration of treatment plans is not solely responsible for the older-age OvCa patient’s unfavorable prognosis. Aging-related genetic changes, including accumulation of mutations, epigenetic modifications, and copy number variations (CNVs), may offer new clues in identifying OvCa prognostic and screening biomarkers.

In this article, the correlation of aging with genetic alterations in The Cancer Genome Atlas Ovarian Cancer (TCGA-OV) dataset was studied. We found copy numbers loss of the F-Box protein FBXL20 predicts OvCa diagnosis at a younger age (<60 years). Moreover, decreased FBXL20
expression as the result of copy number loss predicts favorable overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS).

Methods and materials

Public datasets

The clinical and genetic information of OvCa samples were derived from The Cancer Genome Atlas Ovarian Cancer (TCGA-OV) dataset. Analysis of mutations was conducted based on the Genomic Data Commons (GDC) Data Portal (https://portal.gdc.cancer.gov/). Specifically, 608 OvCa patients were included in TCGA-OV dataset. The Cancer Imaging Archive (TCIA) provides radiological data of 143 OvCa patients (https://www.cancerimagingarchive.net/). Expression levels of genes in the normal tissue were based on the Genotype-Tissue Expression (GTex) project (https://www.gtexanalysis.org/). The data regarding the ‘Longest Dimension’ of TCGA-OV cases was downloaded from the UCSC Xena. Quartiles of genes’ CNVs were used as cutoff values in grouping patients into ‘Upper quartile’, ‘Second quartile’, ‘Third quartile’, and ‘Lower quartile’ cohorts. Survival analyses comparing ‘Upper quartile’ and ‘Lower quartile’ cohorts were presented.

Kaplan-Meier (K-M) survival analysis

K-M analyses of overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) of OvCa patients were carried out based on TCGA-OV dataset. The survival data was downloaded from the UCSC Xena. Quartiles of genes’ CNVs were used as cutoff values in grouping patients into ‘Upper quartile’, ‘Second quartile’, ‘Third quartile’, and ‘Lower quartile’ cohorts. Survival analyses comparing ‘Upper quartile’ and ‘Lower quartile’ cohorts were presented.

Copy number variations (CNVs) of OvCa patients

OvCa patients in TCGA-OV dataset were grouped into different age groups of 26–45, 46–59, 60–75, and 76–89 years based on the age at initial OvCa diagnosis. Prevalence and frequency of each type of mutations and CNVs were analyzed using the Firebrowse (http://firebrowse.org/). CNVs of genes KSR1, TNFAIP1, TRAF4, SLC6A4, NF1, SUZ12 and RAD51D, CCL5, FBXO47, FBXL20, ERBB2, MIEN1 located on chromosome bands 17q11.2 and 17q12, respectively, were identified. Those samples were aligned with patients’ age at initial OvCa diagnosis using the UCSC Xena platform. These genes were selected to represent the CNVs of chromosome bands 17q11.2 and 17q12. Their involvement in carcinogenesis is indicated in the Atlas of Genetics and Cyogenetics in Oncology and Hematology.

Demographic analysis of OvCa patients with differential FBXL20 copy numbers

Patients from TCGA-OV dataset were grouped into higher-than-median copy numbers of FBXL20 (‘FBXL20 High’; n = 227) and lower-than-median copy numbers of FBXL20 (‘FBXL20 Low’; n = 227). The demographics of the two groups, including ethnicity, race, and age at initial OvCa diagnosis, were derived from TCGA-OV. Patients grouped into these groups were further categorized based on age at initial OvCa diagnosis (≤ 49, 50–59, and ≥ 60 years).

FBXL20 expression levels and OvCa staging

Violin plot analysis for OvCa staging and FBXL20 expression levels was carried out on GEPIA (http://gepia2.cancer-pku.cn/index). Briefly, FBXL20 expression levels were transformed with the equation of log2(TPM + 1). Ovarian serous cystadenocarcinoma subtype derived from TCGA-OV dataset was used for the Violin plot analysis. The method for differential gene expression analysis is one-way ANOVA. Proteomic data used in this publication was generated by the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (https://cptac-dataportal.georgetown.edu/) (n = 95) [14]. Mass spectrometry analysis was conducted using the 10-plexed isobaric tandem mass tags (TMT-10). Protein abundance was presented as log2-ratio of the expression of the sample to a normal control. Samples were aligned based on OvCa stages. The protein levels of these aligned cases were then color-coded. Proteins involved in CRL, including FBX20, cullin 1, 2, 3, 4A/B, 5, and 7, were studied. Actin was used as a reference control.

Copy number losses on 17q11.2-q12 and OvCa

To identify potential age-related genetic alterations, we grouped OvCa patients from TCGA-OV dataset into different age groups: 26–45, 46–59, 60–75, and 76–89 years (Fig. 1A). We found even distribution for both the prevalence and types of mutations across different age groups (Supplementary 2). The mutation status of key genes, including TP53, NF1, BRCA1/2, CDK12, RB1, EFEMP1, HNF1B, KRAS, PTEN, ERCC6, LARP1, MT2A, and NRAS, was also not affected by patients’ ages at initial OvCa diagnosis (Supplementary 1). Copy number variations (CNVs) represent a significant source of genetic variation in the human genome [15]. Therefore, we further investigated CNVs between different age groups with OvCa.

We found that most OvCa patients at 26–59 years old (y/o) age group have copy number losses on chromosome band 17q11.2 (Fig. 1A, Supplementary 2). Interestingly, 17q11.2 and its flanking region 17q12 (17q11.2-q12) have been proposed by the Ovarian Cancer Association Consortium (OCAC) as susceptibility loci bearing common germline genetic variations for polygenic risk prediction for OvCa [7]. CNVs of genes KSR1, TNFAIP1, TRAF4, SLC6A4, NF1, SUZ12 and RAD51D, CCL5, FBXO47, FBXL20, ERBB2, MIEN1 located on 17q11.2 and 17q12, respectively, were selected and aligned with patients’ age at initial OvCa diagnosis (Fig. 1B, C). These genes were selected based on their locations on the genome and their involvement in carcinogenesis. Consistent with Fig. 1A, loss of copy numbers of individual genes on 17q11.2-q12 correlates with OvCa diagnosis at a younger age (Fig. 1B, C).

CNVs of genes on 17q11.2-q12 and OvCa prognosis

CNVs of each oncology-related gene on 17q11.2-q12 were studied. We found copy numbers of 4 genes, including F-box only protein 47 (FBXO47), F-box/LRR-repeat protein 20 (FBXL20), erb-b2 receptor tyrosine kinase 2 (ERBB2), and migration and invasion enhancer 1 (MIEN1), can predict OvCa survival rates. The P-values between ‘Upper quartile’ and ‘Lower
markers, including mutation status of FBXL20 expression levels of mutation status can predict OvCa prognosis (Fig. 3A). Furthermore, we right panels).

ERBB2 disease-free survival (DFS), and progression-free survival (PFS) with values of 0.0073, 0.0045, and 0.00475, respectively (Fig. 3B, from left to right). FBXO47 and FBXL20 are F-box proteins that function as substrate recognizing proteins in the SKP1-Cullin1-F-box (SCF) E3 complex for ubiquitin (Ub) conjugations [16] (Fig. 7, Table 1). The expression of FBXL20 can be an independent OvCa prognostic biomarker (Supplementary 5). All these data indicate CNVs and expression levels can predict OvCa prognosis. The prognostic role of MIEN1 was not studied due to the lack of RNA-Seq data in TCGA-OV.

FBXL20 copy number loss predicts OvCa diagnosis at a younger age

To study other demographic features of patients with differential FBXL20 expression, OvCa patients in TCGA-OV dataset were grouped into ‘FBXL20 High’ and ‘FBXL20 Low’ cohorts (n = 227 vs. n = 227) using the median CNV value as the cutoff. No significant difference in ethnicity and race exists between the cohorts (data not shown). In the cohort of lower-than-median FBXL20 copy numbers, 26.87% (n = 61), 33.92% (n = 77) and 36.56% (n = 83) of the patients were diagnosed with OvCa at the age of ≤49, 50–59 and ≥60 years, respectively (Fig. 3C). In the cohort with higher-than-median FBXL20 copy numbers, 11.77% (n = 29), 28.63% (n = 65) and 54.19% (n = 123) of the patients were diagnosed with OvCa at the age of ≤49, 50–59 and ≥60 years, respectively (P < 0.001) (Fig. 3C).

Elevated FBXL20 protein levels correlate with malignant histological features of OvCa

The function of FBXL20 in OvCa progression is barely studied. We further studied the clinicopathological features of OvCa subtypes with different cellular levels of FBXL20. Three subtypes of OvCa, including serous, mucinous, and endometrioid, were selected from the Human Protein Atlas. Patients were grouped into ‘FBXL20 Low’ and ‘FBXL20 High’ cohorts based on FBXL20 staining intensity. The serous subtype of OvCa with high FBXL20 staining intensity showed malignant histological phenotypes with micropapillary, trabecular structures, detached tumor cells, and glandular complexity (Fig. 4). The mucinous OvCa subtype with high FBXL20 expression showed malignant features of infiltrative patterns with small glands, nests, and small clusters of floating cells (Fig. 4).

Fig. 1. Genetic variations of OvCa patients diagnosed at different ages A) OvCa patients were grouped into different age groups based on the age at initial diagnosis of the disease. Prevalence (top panel) and frequency of each types of mutations (middle panel) and copy number variations (CNVs) on chromosome band 17q11.2 were plotted in accordance with patient's age B) CNVs of indicated genes on 17q11.2 were aligned with patients' age at initial OvCa diagnosis (n = 606). C) CNVs of indicated genes on 17q12 were aligned with patients' age at initial OvCa diagnosis (n = 606).
subtype with high FBXL20 showed abundant proliferative cells and nuclear atypia (Fig. 4, arrows).

Elevated FBXL20 expression correlates malignant histological features in serous OvCa

Serous subtype is the most common and lethal form of OvCa. Therefore, we further studied histological features of serous OvCa samples with differential FBXL20 expression levels using hematoxylin and eosin (H&E) staining. Serous subtype OvCa patients were grouped into ‘FBXL20 Low’ and ‘FBXL20 High’ cohorts based on expression levels of FBXL20. We found samples with low FBXL20 expression levels (TCGA-23-1111, TCGA-61-2003, TCGA-61-1910) generally have benign features such as psammoma bodies (circles) and less frequent and less extensive necrosis when compared with samples with higher expression levels of FBXL20 (TCGA-13-1511, TCGA-61-1743, TCGA-29-1691) (Fig. 5). These data

![Graph](image.png)

**Fig. 2.** Survival analysis based on copy number variations (CNVs) of individual genes. The upper and lower quartiles were used as cutoff values for classification of patients into groups with ‘high’ or ‘low’ copy numbers of the indicated genes. Hazard ratio for FBXO47, FBXL20, ERBB2, and MIEN1 is: 9.193, 7.115, 10.5, and 10.68, respectively. *: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$.

| Class | F-box protein | Key substrate | Pathway involved | Ovarian cancer |
|-------|---------------|---------------|------------------|---------------|
| FBXWs | FBXW1/11      | Mdm2, Cdc25A, Wee 1, DEPTOR, β-catenin, IkB, AEBP2 | DNA damage response; mTOR pathway; Wnt pathway; NFkB pathway; epigenetic modifications | Cisplatin and Platinum resistance; metastasis; invasion; EMT; cancer stem cell [20,29-33]. PARPi resistance; cancer stem cell; chemo-resistance; angiogenesis [34-39]. |
|       | FBXW7        | c-Myc, Cyclin E, Notch1, Mc1-1, mTOR, HIFα, c-Jun | Cell cycle; Notch pathway, apoptosis, mTOR pathway, HIFα pathway | Tumorigenesis, progression [40-42]. |
|       | FBXW8        | Cyclin D1, IBSI | Cell cycle; PI3K pathway | Cisplatin resistance; invasion; growth and proliferation [43-45]. PARPi resistance; PARPi sensitization [46,47]. Early dissemination [48,49]. |
| FBXLs | FBXL1 (SKP2) | P47, P21, P27, P16, FOXO3, BRCAl, Axl | Cell cycle; apoptosis; FOXO pathway, Akt pathway | Cisplatin resistance; metastasis [21]. |
|       | FBXL3        | c-Myc, TLK2 | Cell cycle; DNA replication; checkpoint signaling | Cisplatin resistance; metastasis [21]. |
|       | FBXL10       | c-Fos | c-Fos pathway; | Cisplatin resistance; metastasis [21]. |
|       | FBXL20       | Vps34 | Phosphatidylinositol production; autophagy | Cisplatin resistance; metastasis [21]. |
| FBXOs | FBXO4        | Cyclin D1, TRF1, FMRP | Cell cycle; telomeres maintenance; RNA binding | Cisplatin resistance; metastasis [21]. |
|       | FBXO7        | TRAF1/2, cIAP1, Gsk3β | Apoptosis; Wnt pathway | Cisplatin resistance; metastasis [21]. |
|       | FBXO22       | Mdm2, LKB1, KDM4B | P53 pathway; DNA damage response; LKB1-AMPK pathway; | Cisplatin resistance; metastasis [21]. |

Table 1: The involvement of F-box proteins in ovarian cancer. The F-box proteins are categorized into sub-families, FBXL, FBXW, and FBXO based on their substrate-binding motifs, including Leucine Rich Repeats, WD40 motifs, and other domains, respectively [35]. Relatively well studied F-box proteins that are related with OvCa progression including FBXW1/11 [27,36–40], FBXW7 [41–46], FBXW8 [47–49], FBXL1 (SKP2) [50–52], FBXL3 [53,54], FBXL10 [55,56], FBXL20 [26], FBXO4 [57,58], FBXO7 [59–61] and FBXO22 [62–64]. Abbreviations: AEBP2, AE binding protein 2; Cdc25A, cell division cycle 25 A; cIAP1, cellular inhibitor of apoptosis protein 1; DEPTOR, DEP domain-containing MTOR interacting protein; FMRP, fragile X mental retardation protein; KDM4B, lysine demethylase 4B; LKB1, liver kinase B1; Mdm2, murine double minute 2 homolog; TLK1/2, tousled-like kinases 1/2; TRAF1/2, TNF receptor associated factor 1/2; TRF1, telomeric repeat factor 1; Vps34, vacuolar protein sorting 34.
Fig. 3. The effect of FBXL20 expression levels on OvCa prognosis. A) ERBB2 expression is aligned with its copy numbers using the UCSC Xena platform based on TCGA-OV dataset (n = 308). Overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) with differential ERBB2 expression levels were compared (from the left to the right panel). The survival of patients with mutated ERBB2 was also plotted against those wildtypes. Hazard ratio for OS, DFS, and PFS is: 1.67, 0.951, and 0.045, respectively. B) The expression of FBXL20 is aligned with its copy numbers (n = 308). OS, DFS and PFS were plotted with differential FBXL20 expression levels as cutoffs. Hazard ratio for OS, DFS, and PFS is: 7.207, 8.09, and 3.929, respectively. C) Demographic of OvCa patients with differential FBXL20 CNVs diagnosed at indicated age groups. *: P < 0.05; **: P < 0.01; ***: P < 0.001.
indicate that elevated FBXL20 expression level is associated with malignant histological phenotypes.

Radiogenomics of OvCa samples with differential FBXL20 expression

We further evaluated whether the histological features of clinical samples with FBXL20 differential expression correlated with radiographic phenotypes. Computerized tomography (CT) images from The Cancer Imaging Archive (TCIA) were employed. Patients were grouped into ‘FBXL20 Low’ and ‘FBXL20 High’ cohorts based on the median expression level of FBXL20. Samples with low FBXL20 expression levels (TCGA-13-0799, TCGA-61-2003, TCGA-61-1910) generally have benign features such as thick encapsulation (arrows) and calcification (red circles) (Fig. 6A). Samples with high FBXL20 expression levels (TCGA-13-1511, TCGA-10-0936, TCGA-09-2044) frequently have features of invasive spreading and extensive necrosis (Fig. 6A). Tumor volumetry is closely related with OvCa staging and prognosis [23]. To further investigate the correlation between radiographical features with differential FBXL20 expression levels, we analyzed the tumor sizes of ’FBXL20 Low’ and ’FBXL20 High’ cohorts. We found patients with higher-than-median (n = 191) FBXL20 expression levels have larger tumor size as reflected by the ‘Longest Dimension’ than those with lower-than-median (n = 190) expression levels (P = 0.002) (Fig. 6B). These data suggest that elevated FBXL20 expression is associated with more malignant radiographical features and larger tumor sizes, highlighting the potential of integrating FBXL20 expression levels in radiogenomic studies for a more informative diagnostic workup of OvCa cases.

Discussion

The prognosis for advanced-stage OvCa remains dismal despite intensive chemotherapy and cytoreduction [24]. Based on 2018 data, approximately 22,000 new OvCa cases were diagnosed with over 14,000 deaths in the United States, making OvCa the most lethal and the second most common gynecologic malignancy in western countries [24]. The early dissemination of OvCa cells complicated surgical debulking. Meanwhile, chemoresistance develops with recurrent regimens, leading to frequent relapses and high mortality rates [24]. Based on the study of age-specific genetic information, we identified CNVs and expression levels of FBXL20 as valuable markers in predicting OvCa patients’ overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). We
identified a unique group of OvCa patients with FBXL20 copy number loss who will have a much higher percentage of OvCa diagnosis at a younger age (over 60% diagnosed at age >60 years) (Fig. 3C). These patients generally have better clinical outcomes than patients with FBXL20 copy number amplification. Therefore, screening of FBXL20 copy numbers may help identify patients who might benefit from clinical workup at a younger age for the purpose of OvCa early detection.

The human genome contains 69 of F-box proteins that recognize substrates for Ub conjugations via the Skp1-Cullin1-F-box (SCF) E3 ubiquitin ligase [16]. Table 1 provides a non-exhaustive list of relatively well-studied F-box proteins involved in OvCa progression. Pathways regulated by those F-box proteins play pivotal roles in OvCa early dissemination, progression, chemoresistance, and metastasis (Table 1). One well-studied substrate of FBXL20 is the vacuolar protein-sorting 34 (Vps34), also known as phosphatidylinositol 3-kinase catalytic subunit type 3 (PI3KC3), which mainly functions in the initiation of autophagy [25]. DNA damage response (DDR) triggers Vps34 phosphorylation, and subsequent FBXL20-mediated polyubiquitination and degradation can dampen the induction of autophagy [26].

The exact roles of FBXL20 in OvCa progression remains unclear. Nevertheless, our data indicate that the downregulation of FBXL20 activities may improve OvCa clinical outcomes. Besides Vps34, other key proteins involved in DDR, including Wee1, checkpoint kinase 1 (CHK1), p21, and cell division cycle 25 A (CDC25A), are SCF E3 ligase substrates [27–31] (Fig. 7, Table 1). Fully activation of CRLs requires conjugation of an ubiquitin (Ub)-like protein called neural precursor cell-expressed developmentally downregulated 8 (NEDD8) to near the C-terminus of cullin1 in the SCF complex [32]. Conjugation of NEDD8 to cullins is carried out in three enzymatic steps involving NEDD8-activating enzyme (NAE; E1), UBC12 and Ube2F (E2s) and E3s (Fig. 7). The NEDD8 conjugation can be inhibited

Fig. 6. Computerized tomography (CT) scan of OvCa cases with differential FBXL20 expression levels. A) OvCa patients was grouped into ‘FBXL20 Low’ and ‘FBXL20 High’ cohorts based on the median expression level of FBXL20. CT images of OvCa patients with differential FBXL20 expression levels. Features of encapsulation (arrows) and calcification (red circles) and necrosis (yellow circles) were indicated. B) The longest dimensions of OvCa cases in the ‘FBXL20 Low’ (n = 190) and ‘FBXL20 High’ (n = 191) cohorts were presented. The dimensions were measured in centimeters (cm). **: P < 0.01. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 7. FBXL20 as a substrate recognizing protein in the Skp1-Cullin1-F-box (SCF) E3 ligase. Schematic overview of how Age-related CNVs of FBXL20 can affect its expression and thus regulate SCF-mediated degradation of substrates recognized by FBXL20.
by its first-in-class inhibitor pevonedistat and, by doing so, shutting down the Ub-conjugation activities of the SCF complex. Indeed, pre-clinical data showed that pevonedistat treatment induced significant DDR activation in OvCa, with no overlapping sensitivity profile with cisplatin/platinum [33,34]. As such, the therapeutic eradication of FBXL20 activities via pevonedistat-mediated inhibition of NEDD8 conjugation may offer similar survival advantage as those with less FBXL20 expression.

CRediT authorship contribution statement

Shuhua Zheng: Conceptualization, Investigation, Methodology, Writing-Original draft preparation Yuejun Fu: Data curation, Writing-Original draft preparation, Supervision, Writing-Reviewing and Editing.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tranon.2020.100863.

References

[1] A.J. Cortez, P. Tudrej, K.A. Kujawa, K.M. Lisowska, Advances in ovarian cancer therapy, Cancer Chemother. Pharmacol. 81 (2018) 17–38.
[2] S.J. Chang, R.E. Bristow, D.S. Chi, W.A. Chiby, Role of aggressive surgical cytoreduction in advanced ovarian cancer, J. Gynecol. Oncol. 26 (2015) 336–342.
[3] E. Frazzene, S. Centonze, A. Diana, F. Carlino, L.P. Guerrera, M. Di Napoli, F. De Vitis, S. Pignata, F. Gardiello, M. Ordinati, PARP inhibitors in ovarian cancer, Cancer Treat. Rev. 73 (2019) 1–9.
[4] K. Kotosopoulou, J. Grunwald, B. Karlan, B. Rosen, T. Huzarski, P. Moller, H.T. Lynch, C.F. Singer, L. Senter, S.L. Neuhausen, et al., Age-specific ovarian cancer risks among women with a family history of breast cancer, Am. J. Obstet. Gynecol. 190 (2004) 1398–1400.
[5] C. Mehner, A.L. Oberg, K.R. Kalli, M.J. Maurer, A. Nassar, E.L. Goode, A. Nassar, E.L. Goode, A. Nassar, E.L. Goode, et al., Proteomics. tissue-based map of DDR activation in ovarian cancers: possible role in predicting chemoresistance, Cancer J. 6 (2000) 589–590.
[6] J. Jin, T. Cardoso, R.C. Lovingier, S.J. Elledge, M. Pagano, J.W. Harper, Systemic analysis of gene expression changes in F-box proteins, Genes Dev. 18 (2004) 2573–2580.
[7] P.P. Kashwaha, S. Gupta, A.K.K. Singh, S. Kamar, Emerging role of migration and invasion enhancer 1 (MEN1) in cancer progression and metastasis, Front. Oncol. 9 (2019) 868.
[8] E. Teplinsky, F. Muggia, Targeting HER2 in ovarian and uterine cancers: challenges and future directions, Gynecol. Oncol. 135 (2014) 364–370.
[9] K. Xu, S. Yang, Z. Zhao, Prognostic significance of BRCA mutations in ovarian cancer: an updated systemic review with meta-analysis, Oncotarget 8 (2017) 285–302.
[10] S. Lahrambiwe, W. Chapman, J. McLaughlin, L.L. Andrusi, p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance, Cancer J. 6 (2000) 302–308.
[11] H.L. Yu, X.D. Ma, J.F. Tong, Q.J. Li, X.J. Guan, J.J. Yang, WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells, Oncotarget 12 (2019) 6191–6201.
[12] C. Mehner, A.L. Oberg, K.R. Kalli, M.J. Maurer, A. Nassar, E.L. Goode, G.L. Keeney, A. Jatoi, D.C. Radisky, et al., EGRF as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review, Genes Dis 8 (2017) 589–590.
[13] J. Prat, Oncology PGCo, Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the international federation of gynecology and obstetrics (FIGO), Obstet. Gynecol. 126 (2015) 171–174.
[14] L.A. Torre, B. Trabert, C.E. DeSantis, K.D. Miller, G. Samimi, C.D. Runowicz, M.M. Gaudet, A. Jemal, R.L. Siegel, Ovarian cancer statistics, 2018, CA Cancer J. Clin. 68 (2018) 284–296.
[15] J.H. Hudley, L.N. Young, Mechanisms of apoptosis initiation, Annu. Rev. Biochem. 86 (2017) 225–244.
[16] J. Xiao, T. Zhang, D. Xu, H. Wang, Y. Cai, T. Jin, M. Liu, M. K. Ju, Y. Yuan, FBXL20-mediated Vps4 ubiquitination as a p53 controlled checkpoint in regulating autophagy and tumor degradation, Mol. Cancer Ther. 15 (2015) 184–194.
[17] J. Jin, J. Shiorgone, L. Xu, G. Nalepa, J. Qin, S.J. Elledge, J.W. Harper, SCFbeta-TrCP links Chk1 signaling to degradation of the Cd25A protein phosphatase, Genes Dev. 17 (2003) 3062–3074.
[18] W. Zhong, H. Feng, F.L. Santiago, E.T. Kipreos, CUL4 ubiquitin ligase maintains genome stability by restraining DNA replication licensing, Nature 423 (2003) 885–889.
[19] C.A. Lovejoy, K. Lock, A. Yenamandra, D. Cortez, DDB1 maintains genome integrity through regulation of Cdh1, Mol. Cell. Biol. 26 (2006) 7797–7800.
[20] M. Besenjestad, J. Jouabie, T. Jacquet, H. Bridgeman, V. Bartkova, A. Sarasin, A. Fotedar, R. Fotedar, UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair, Cell 114 (2003) 599–610.
[21] Y.W. Zhang, J. Brognaard, C. Coughlin, Z. You, M. D'Olied-Filhart, A. Aslanian, G. Mangione, R.T. Abraham, T. Hunter, The F-box protein Fbw8 regulates Chk1 stability and cellular sensitivity to replication stress, Mol. Cell 35 (2009) 442–453.
[22] L. Zhou, W. Zhang, Y. Sun, J. Jia, Protein neddylation and its alterations in human cancers for targeted therapy, Cell. Signal. 44 (2018) 95–102.
[23] A.A. Jazarei, E. Shibata, J. Park, J.L. Bryant, M. Conway, K.S. Modest, P.G. Smith, M.A. Milhollen, A.J. Berger, A. Dutta, Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924, Mol. Cancer Ther. 12 (2013) 1956–1967.
[24] S.T. Nawrocki, K.R. Kelly, P.G. Smith, C.M. Espitia, A. Possemolel, S.A. Benassouli, M. Milhollen, S. Blakemore, M. Thomas, A. Berger, et al., Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer, Clin Cancer Res. 19 (2013) 3577–3590.
[25] S.J. Randle, H. Laman, P. De Brabander, C. Plante, Interactions with the hallmark pathways in cancer, Semin. Cancer Biol. 36 (2016) 3–17.
[26] Z. Wang, J. Zhong, D. Gao, H. Inuzuka, P. Liu, W. Wei, DEPTOR ubiquitination and destruction by SCF(beta-TrCP), Am. J. Physiol. Endocrinol. Metabol. 302 (2012) E162–E169.
[27] Y. Sun, S. Li, L. Yang, D. Zhang, Z. Zhao, J. Gao, L. Liu, CD25A facilitates chemoresistance in ovarian cancer multicellular spheroids by promoting e-cadherin expression and arresting cell cycles, J. Cancer 10 (2019) 2874–2884.
[28] R.C. Arend, A.J. Londondo-Joshi, J.M. Straughn Jr., D.J. Buchsbaum, The Wnt/beta-catenin pathway in ovarian cancer: a review, Gynecol. Oncol. 131 (2013) 772–779.
[29] C.D. House, E. Jordan, L. Hernandez, M. Osaki, J.M. James, M. Kim, M.J. Kruhlak, E. Batchelor, F. Elloumi, M.C. Mann, et al., NFkappaB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH (+) Cancer Stem-like Cells via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH (+) Cancer Stem-like Cells.
[30] Y. Xu, C. Tian, J. Qu, J. Wang, W. J. Zhang, W. Wang, X. Zhao, J. Guo, Z. Shao, Z. Zhao, J. Guo, L. Liu, CD25A facilitates chemoresistance in ovarian cancer multicellular spheroids by promoting e-cadherin expression and arresting cell cycles, J. Cancer 10 (2019) 2874–2884.
H. Okabe, S.H. Lee, J. Phuchareon, D.G. Albertson, F. McCormick, O. Tetsu, A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation, PLoS One 1 (2006), e128.

M.L. Gasparri, E. Bardhi, I. Ruscito, A. Papadia, A.A. Farooqi, C. Marchetti, G. Bogani, I. Ceccacci, M.D. Mueller, P. Benedetti Panici, PI3K AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Geburtshilfe Frauenheilkd. 77 (2017) 1095–1103.

F. Scheufele, B. Wolf, M. Kruse, T. Hartmann, J. Lempart, S. Muhlic, A.F.H. Pfeiffer, L.J. Field, M.J. Charron, Z.Q. Pan, et al., Evidence for a Regulatory Role of Cullin-RING E3 Ubiquitin Ligase 7 in Insulin Signaling Cell Signal 26, 235–239, 2014.

F. Wang, C.H. Chan, K. Chen, X. Guan, H.K. Lin, Q. Tong, Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation, Oncogene 31 (2012) 1546–1557.

G. Wang, C.H. Chan, Y. Gao, H.K. Lin, Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis Chin J Cancer 31 (2012) 169–177.

K. Shigemasa, L. Gu, T.J. O’Brien, K. Ohama, Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma, Clin. Cancer Res. 9 (2003) 1756–1763.

J.B. Lee, S. Segura-Rayona, M. Villamor-Paya, G. Saredi, M.A.M. Todd, C.S. Attolini, T.Y. Chang, T.H. Stracker, A. Groth, Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors, Sci. Adv. 4 (2018) eaat4985.

A.L. Huber, S.J. Papp, A.B. Chan, E. Henriksen, S.D. Jordan, A. Kriebs, M. Nguyen, M. Wallace, Z. Li, C.M. Metallo, et al., CRβ2 and FBX15 Cooperatively Degrade c-MYC Mol Cell 64, 774–789, 2016.

X.R. Han, Z. Zha, H.X. Yuan, X. Feng, Y.K. Xin, Q.Y. Lei, K.L. Guan, Y. Xiong, KDM2B/FBXO10 targets c-Fos for ubiquitination and degradation in response to mitogenic stimulation, Oncogene 35 (2016) 4179–4190.

L. Oliveira-Ferrer, K. Rossler, V. Haustein, C. Schroder, D. Wicklein, D. Maltese, N. Khaustova, T. Samatov, A. Tonevitsky, S. Mahner, et al., e-FOS suppresses ovarian cancer progression by changing adhesion, Br. J. Cancer 110 (2014) 753–763.